Vesilut

Identified and synthesised by Vladimir Kh. Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, Russia, as part of the organ-specific 'cytogen' directed-synthesis programme. The parent polypeptide extract is derived from urinary bladder tissue of bovine origin; glutamic acid and aspartic acid were identified as the enriched residues at regulatory gene-promoter sites in urothelial and detrusor smooth muscle cells. The active peptide complex is internally designated AKS-M (peptide complex: L-aspartic acid, L-glutamic acid). Marketed in Russia as a biologically active food supplement under the brand names Vesilut® (TD Peptid Bio / St. Petersburg Institute) and Vesilyut® (Firma-Vita). The same dipeptide is sold globally as lyophilised research powder under the spelling Vesilute. Related clinical-grade polypeptide preparation: Vezusten® and Vesusten® (longer-chain bladder-tissue polypeptide complex, same therapeutic target). Introduced to Western research-chemical markets approximately 2019–2021.

Vesilut (Glu-Asp) acts through epigenetic chromatin remodelling and direct DNA interaction consistent with the class mechanism established across Khavinson short-chain peptides. The proposed cascade is: (1) the dipeptide penetrates nuclear membranes and binds within the major groove of double-stranded DNA — PubChem documents that glutamic acid in its extended conformation disrupts up to three hydrogen bonds in dsDNA, destabilising condensed chromatin architecture (PMC8619776, PMID 34834147); (2) this decondensation shifts the 30-nm chromatin fibre toward the 10-nm open nucleosomal filament state, reactivating genes whose promoters were silenced by age-related heterochromatinisation; (3) in bladder-specific cell populations the proposed downstream effects include re-expression of urothelial differentiation factors, restoration of tight-junction protein synthesis, and reduced expression of pro-inflammatory cytokines; (4) in smooth muscle (detrusor) cells the peptide is hypothesised to interfere with calcium-dependent glycogen aggregation, reducing pathological contractile tone and restoring normal detrusor compliance — a mechanism analogous to the glycogen-disaggregation pathway proposed for related Prostamax studies in prostate smooth muscle (Borovskaya et al. 2013, DOI 10.4236/mri.2013.23007); (5) Glu in the dipeptide carries a net negative charge at physiological pH, complementing electrostatic interaction with the positively charged histone H1 linker domain — consistent with histone engagement observed for related Khavinson di- and tetrapeptides including Epithalon (AEDG, PMID 32019204) and KE; (6) at the tissue level, experimental models report reduction of mast-cell infiltration, mucosal oedema, urothelial erosion, and submucosal fibrotic changes following administration; (7) vascular microcirculation in the bladder wall is proposed to improve through smooth muscle relaxation in arteriolar walls, enhancing oxygen and nutrient delivery to regenerating urothelium. The Khavinson 2021 systematic review (PMID 34834147) contextualises the interaction mechanism for the broader class without reporting Vesilut-specific binding constants; no independent biophysical spectroscopy of Glu-Asp DNA binding has been published as of May 2026.

Rat model of bladder irritation / infravesical obstruction: normalisation of detrusor contractility parameters; approximately 40% reduction in tissue damage scores; faster mucosal healing compared to untreated controls (Biolongevitylabs.com research compilation, referencing unpublished or Russian-language primary data); Rat model (detailed source not independently verified): reduction of mast-cell infiltration, submucosal oedema, and urothelial erosion; In vitro (cell culture): upregulation of urothelial protective proteins and reduction of inflammatory messengers by approximately 50% (community-compiled source, primary citation unclear); Clinical — Kovalev et al. 2024 prospective cohort (n=20, idiopathic OAB women): daily urinations reduced from 14.0 [13.0; 16.3] to 11.0 [8.8; 12.0] (p<0.001); urge incontinence episodes reduced (p=0.004); maximum cystometric capacity increased from 267 [158; 332] to 320 [267; 433] ml; OAB questionnaire score decreased from 28 [22; 30] to 19 [14; 24] (p=0.001); nocturia reduced from 4 to 2 episodes (p<0.001); no adverse effects reported in any patient (DOI 10.21886/2308-6424-2024-12-4-50-56, treatment agent: Vezusten, same bladder polypeptide complex class); Clinical — Galkina and Galkin, ICS-EUS 2025 (n=48, OAB): Vezusten IM 5 mg × 10 doses over 42 days; nocturia frequency reduced by more than 2.7-fold; patients with no nighttime awakening increased from 10% to 38%; statistically significant improvement in TUFS, PPIUS, OAB-q (p=0.0000); benefits stable 3 weeks post-treatment; Epidemiological context: Khavinson (2002) described 20–40% lifespan extensions in rodent models across the broader bioregulator programme; Vesilut-specific longevity data have not been published.